IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients
This study has been completed.
Sponsor:
Peter Daley
Collaborator:
Dalhousie University
Information provided by (Responsible Party):
Peter Daley, Christian Medical College
ClinicalTrials.gov Identifier:
NCT00366470
First received: August 18, 2006
Last updated: July 4, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
There is some evidence that supplemental Vitamin D may contribute to quicker recovery from TB when given in addition to normal TB therapy. This needs to be proven with a controlled clinical trial. People receiving Vitamin D with anti TB therapy will be compared against people receiving anti TB therapy alone to see if vitamin D contributes to a quicker recovery (as shown by a quicker sputum culture conversion).
| Condition | Intervention | Phase |
|---|---|---|
| Pulmonary Tuberculosis | Drug: A. 100,000 IU Cholecalciferol per dose of 3.3ml Other: B. Migliol Oil without Cholecalciferol | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Double Blind, Randomized, Parallel, Placebo Control Design Study to Determine the Effect of Addition of Vitamin D to Conventional Anti TB Therapy |
Resource links provided by NLM:
Further study details as provided by Peter Daley, Christian Medical College:
Primary Outcome Measures:
- Time to sputum culture conversion [ Time Frame: 8 weeks of treatment ]
Secondary Outcome Measures:
- Percent of Patients Culture Positive [ Time Frame: 8 Weeks ]
- Performance Status [ Time Frame: 8 Weeks ]
- Time To Sputum Smear Conversion [ Time Frame: Continous ]
- Proportion of Patients Smear Positive [ Time Frame: 4 Weeks, 8 Weeks, 12 Weeks ]
- Time To Growth In Liquid Media [ Time Frame: 8 Weeks ]
- RNTCP Treatment Outcomes [ Time Frame: 24 Weeks ]
- Weight Gain [ Time Frame: 8 Weeks ]
| Enrollment: | 250 |
| Study Start Date: | November 2009 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
Vitamin D in doses of 100,000 IU
|
Drug: A. 100,000 IU Cholecalciferol per dose of 3.3ml
100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
|
| Placebo Comparator: B |
Other: B. Migliol Oil without Cholecalciferol
3.3 ml Migliol Oil, every two weeks for two months
|
Detailed Description:
The proposed study is a parallel, randomized, double-blinded, placebo-controlled clinical trial to quantify the change, if any, in microbiological outcome in TB patients treated with vitamin D in combination with standard DOTS therapy. It will take place in four South Indian DOTS centres. The required sample size is 250 patients receiving ATT, to be randomised in a 1:1 fashion (125 patients to receive vitamin D and 125 patients to receive placebo).
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Newly diagnosed smear positive pulmonary tuberculosis.
- Age between 18 to 75 years
- No pre-existing liver or renal disease
- Available for return visits as outlined in the trial protocol
- A Firm home address
Exclusion Criteria:
- Extra-pulmonary or smear negative tuberculosis
- Patients receiving steroids, cytotoxic drugs, post transplant or metastatic malignancy, or not expected to survive for the duration of ATT
- Pregnant or lactating women
- Active diarrhoea, indicating possible fat-soluble vitamin malabsorption.
- Baseline Hypercalcemia >10.5 mg/dl
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00366470
Please refer to this study by its ClinicalTrials.gov identifier: NCT00366470
Locations
| India | |
| Christian Medical College | |
| Vellore, Tamil Nadu, India, 632004 | |
| Bethesda Hospital | |
| Ambur, Tamilnadu, India, 635 802 | |
Sponsors and Collaborators
Peter Daley
Dalhousie University
Investigators
| Principal Investigator: | Dilip Mathai, MD, FCAMS | Christian Medical College, Vellore, India |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Peter Daley, Lecturer, Christian Medical College |
| ClinicalTrials.gov Identifier: | NCT00366470 History of Changes |
| Other Study ID Numbers: |
TB-VitaminD CTRI/2007/091/000008 ( Registry Identifier: Clinical Trials Registry of India ) |
| Study First Received: | August 18, 2006 |
| Last Updated: | July 4, 2012 |
Additional relevant MeSH terms:
|
Tuberculosis Tuberculosis, Pulmonary Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Lung Diseases Respiratory Tract Diseases Respiratory Tract Infections |
Vitamins Vitamin D Ergocalciferols Cholecalciferol Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents |
ClinicalTrials.gov processed this record on August 16, 2017